<DOC>
	<DOCNO>NCT01751984</DOCNO>
	<brief_summary>This study assess LDL-C lower efficacy safety ETC-1002 versus placebo subject hypercholesterolemia history statin intolerance .</brief_summary>
	<brief_title>A Study Efficacy Safety ETC-1002 Subjects With Statin Intolerance</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Key A history statin intolerance begin statin treatment resolve within 4 week stop statin treatment For subject current lipidregulating drug LDLC 100220 mg/dL triglyceride &lt; 350 mg/dL ( prior washout lipidregulating drug supplement ) For subject current lipidregulating drug LDLC 115270 mg/dL fast TG &lt; 400 mg/dL Key Acute significant cardiovascular disease Poorly control hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>lipid-lowering drug</keyword>
	<keyword>statin intolerance</keyword>
</DOC>